Bio Jonathan EN

Jonathan Cool

A dynamic and accomplished entrepreneur, founder, senior executive, board member, strategic consultant, and investor with over 35 years of experience driving innovation in high-tech industries, Mr. Cool has founded, developed, and taken public or participated in the acquisition of several biotechnology and biopharmaceutical companies, including Human Genome Sciences, Molecular Devices, and Gene Networks. He has played a key role in negotiating strategic partnerships with leading multinational pharmaceutical companies, including Glaxo Smith Kline, Sanofi, Schering Plough (now Merck), Takeda, Nono Nordisk, Roche, and Pfizer, securing hundreds of millions of dollars in funding to support research, development, and clinical trials.

He has served on numerous boards of directors of private and public U.S. companies, including Nasdaq-listed companies, in the biotechnology, biopharmaceutical, medical device, and healthcare delivery sectors. Previously, he was President of Biovotion AG, a Swiss medical device company, and Partner of St. Clair Commons, a patient-centric medical campus integrating research, innovation, and healthcare delivery, and Executive Director of the Cleveland Clinic hospital system’s venture capital fund.

He began his career at Bain & Company, before embarking on founding, leading, and managing high-tech companies in pharmaceuticals, medical devices, genomics, drug delivery, patient-centered medicine, biological sensors, and materials science.

He currently serves as Chief Executive Officer of Ultra High Materials, a U.S.-based early-stage specialty chemicals and materials science company that uses proprietary chemistry and processes to develop environmentally smart, high-performance materials. With international experience spanning the United States, Asia, the European Union, China, and Russia, Mr. Cool has successfully advanced technological innovation from concept to commercialization, creating lasting value for patients, consumers, scientists, engineers, and shareholders.

He holds an MBA from Harvard Business School and a BS in Human Biology, cum laude, and honors from Stanford University.